ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. Consun Pharmaceutical Group's annualized return on invested capital (ROIC %) for the quarter that ended in Dec. 2023 was 38.79%.
As of today (2024-06-03), Consun Pharmaceutical Group's WACC % is 7.49%. Consun Pharmaceutical Group's ROIC % is 33.75% (calculated using TTM income statement data).
Consun Pharmaceutical Group generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.
Consun Pharmaceutical Group ROIC % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Consun Pharmaceutical Group's ROIC %
For the Drug Manufacturers - Specialty & Generic subindustry, Consun Pharmaceutical Group's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Consun Pharmaceutical Group's ROIC % Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Consun Pharmaceutical Group's ROIC % distribution charts can be found below:
* The bar in red indicates where Consun Pharmaceutical Group's ROIC % falls into.
Consun Pharmaceutical Group ROIC % Calculation
Consun Pharmaceutical Group's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Dec. 2023 is calculated as:
Note:
The Operating Income data used here is two times the semi-annual (Dec. 2023) data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Consun Pharmaceutical Group (HKSE:01681) ROIC % Explanation
ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.
There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.
Why is ROIC % important?
Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.
As of today, Consun Pharmaceutical Group's WACC % is 7.49%. Consun Pharmaceutical Group's ROIC % is 33.75% (calculated using TTM income statement data).
Consun Pharmaceutical Group generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.
Consun Pharmaceutical Group earns returns that do not match up to its cost of capital. It will destroy value as it grows.
Be Aware
Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Consun Pharmaceutical Group ROIC % Related Terms
Thank you for viewing the detailed overview of Consun Pharmaceutical Group's ROIC % provided by GuruFocus.com. Please click on the following links to see related term pages.
Consun Pharmaceutical Group (HKSE:01681) Business Description
Consun Pharmaceutical Group Ltd is a biotechnology company with sales operations throughout China. Its principal activities are making and selling pharmaceutical products. The company has two reportable segments: the Consun pharmaceutical segment, which is the key revenue driver, and makes and sells modern Chinese medicines and medical contrast medium, and the Yulin pharmaceutical segment, which manufactures and sells traditional Chinese medicines. Consun derives revenue from kidney medicines, contrast mediums, orthopedics medicines, dermatologic medicines, hepatobiliary medicines, medicines for women and children, and others.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:01681 has been successfully added to your 